Erratum: Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2–positive breast cancer (Journal of Clinical Oncology (2011) 29 (351-354) DOI: 10.1200/JCO.2010.31.6679);Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2 - Positive breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 351-354

  Isakoff, Steven J ^a   Baselga, Jose ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALICHEAMICIN; CAPECITABINE; CYTOTOXIC AGENT; DM1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NERATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ASSESSMENT; DIARRHEA; DIMERIZATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MAXIMUM TOLERATED DOSE; METASTATIC BREAST CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL;

EID: 79952088805     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02189     Document Type: Erratum

References (30)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
2. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
3. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
6. Burris HA 3rd, Al E: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) - positive breast cancer after HER2-directed therapy. J Clin Oncol 29:398-405, 2011
7. Bross PF, Beitz J, Chen G, et al: Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496, 2001 (Pubitemid 32708610)
8. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008
9. Junttila T, Fields C, Li1 G, et al: Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel. EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, October 21-24, 2008
10. Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
11. Krop I, LoRusso P, Miller KD, et al: A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients previously treated with lapatinib, trastuzumab, and chemotherapy. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 5090)
12. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27:1999-2006, 2009
13. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
14. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabre-fractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
15. Adams CW, Allison DE, Flagella K, et al: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717-727, 2006
16. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002 (Pubitemid 41039113)
17. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004 (Pubitemid 38482068)
18. Scheuer W, Friess T, Burtscher H, et al: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330-9336, 2009
19. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144, 2010
20. Baselga J, Cortés J, Fumoleau P, et al: Pertuzumab and trastuzumab: Re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: A new biological and clinical observation. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 5114)
21. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
22. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
23. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
24. Denlinger CS, Beeram M, Tolcher AW, et al: A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. J Clin Oncol 28:24s, 2010 (suppl; abstr TPS169)
25. Hurvitz SA, Pegram MD, Lin L-S, et al: Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 6094)
26. Modi S, Stopeck AT, Gordon MS, et al: Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 25:5410-5417, 2007 (Pubitemid 350232217)
27. Robinson MK, Hodge KM, Horak E, et al: Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99:1415-1425, 2008
28. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
29. Miller K, Gianni L, Andre F, et al: A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). J Clin Oncol 28:117s, 2010 (suppl; abstr 1012)
30. Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007 (Pubitemid 47073544)